Monopar Therapeutics (NASDAQ:MNPR) Cut to Sell at Wall Street Zen

Monopar Therapeutics (NASDAQ:MNPR) was downgraded by equities researchers at Wall Street Zen from a “hold” rating to a “sell” rating in a report released on Sunday.

Several other analysts have also recently weighed in on the company. UBS Group set a $105.00 price target on Monopar Therapeutics in a report on Monday, June 29th. BTIG Research boosted their price objective on Monopar Therapeutics from $104.00 to $117.00 and gave the stock a “buy” rating in a report on Tuesday, June 30th. HC Wainwright restated a “buy” rating and issued a $105.00 price objective on shares of Monopar Therapeutics in a research report on Monday, June 29th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Monopar Therapeutics in a research note on Tuesday, April 21st. Finally, Chardan Capital reiterated a “buy” rating and set a $100.00 target price on shares of Monopar Therapeutics in a research report on Monday, March 30th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Monopar Therapeutics currently has an average rating of “Buy” and an average target price of $108.75.

Monopar Therapeutics Trading Up 2.0%

Shares of Monopar Therapeutics stock traded up $2.10 during trading on Friday, hitting $106.60. The stock had a trading volume of 149,262 shares, compared to its average volume of 167,798. The firm has a market cap of $714.22 million, a price-to-earnings ratio of -56.10 and a beta of 1.46. Monopar Therapeutics has a 12 month low of $29.18 and a 12 month high of $112.57. The business’s 50-day moving average is $71.07 and its 200 day moving average is $63.87.

Monopar Therapeutics (NASDAQ:MNPR) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.41. As a group, equities analysts expect that Monopar Therapeutics will post -2.82 EPS for the current year.

Institutional Trading of Monopar Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Russell Investments Group Ltd. bought a new position in Monopar Therapeutics during the third quarter valued at approximately $28,000. BNP Paribas Financial Markets lifted its holdings in shares of Monopar Therapeutics by 100.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 696 shares of the company’s stock worth $57,000 after acquiring an additional 349 shares during the last quarter. Meeder Asset Management Inc. bought a new stake in shares of Monopar Therapeutics in the 4th quarter worth approximately $65,000. JPMorgan Chase & Co. boosted its stake in shares of Monopar Therapeutics by 1,821.0% in the 2nd quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company’s stock valued at $69,000 after purchasing an additional 1,821 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in shares of Monopar Therapeutics during the 2nd quarter valued at $80,000. Hedge funds and other institutional investors own 1.83% of the company’s stock.

Monopar Therapeutics Company Profile

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.